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Elevated oxidative stress has been characterized in numerous disorders including systemic hypertension, arterial 
stiffness, left ventricular hypertrophy (LVH) and heart failure. The peroxisome proliferator activated receptor 
gamma (PPARγ) ameliorates oxidative stress and LVH. To test the hypothesis that PPARγ decreased LVH and 
cardiac fibrosis in chronic pressure overload, in part, by increasing SOD, eNOS and elastin and decreasing NOX4, 
MMP and collagen synthesis and degradation, chronic pressure overload analogous to systemic hypertension 
was created in C57BL/6J mice by occluding the abdominal aorta above the kidneys (aortic stenosis-AS). The 
sham surgery was used as controls. Ciglitazone (CZ, a PPARγ agonist, 4 µg/ml) was administered in drinking 
water. LV function was measured by M-Mode Echocardiography. We found that PPARγ protein levels were 
increased by CZ. NOX-4 expression was increased by pressure-overload and such an increase was attenuated by 
CZ. SOD expression was not affected by CZ. Expression of iNOS was induced by pressure-overload, and such an 
increase was inhibited by CZ. Protein levels for MMP2, MMP-9, MMP-13 were induced and TIMP levels were 
decreased by pressure-overload. The CZ mitigated these levels. Collagen synthesis was increased and elastin 
levels were decreased by pressure-overload and CZ ameliorated these changes. Histochemistry showed that CZ 
inhibited interstitial and perivascular fibrosis. Echocardiography showed that CZ attenuated the systolic and 
diastolic LV dysfunction induced by pressure-overload. These observations suggested that CZ inhibited 
pressure-overlaod-induced cardiac remodeling, and inhibition of an induction of NOX4, iNOS, MMP-2/MMP-13 
expression and collagen synthesis/degradation may play a role in pressure-overload induced cardiac 
remodeling. 
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1.  Introduction 
The communication and chemical gradient 
between the endothelium to myocyte and myocyte to 
myocyte is very important in maintaining the patency 
of the organ such as the heart. Extracellular matrix 
(ECM) connects the myocyte to myocyte, and to the 
endothelial cells [1]. Studies from our laboratory 
demonstrated a direct link between diastolic heart 
failure (DHF), interstitial fibrosis, and left ventricular 
hypertrophy (LVH). There was a 
disconnection/uncoupling between cardiomyocytes 
and endothelial cells by MMP-mediated collagen 
breaks [2]. Although elevated oxidative stress has been 
characterized in numerous disorders including 
systemic hypertension, arterial stiffness, LVH, and 
DHF, the mechanism and link between oxidative stress 
and collagen breaks, LVH, DHF and fibrosis is unclear. 
Peroxinitrite-thiol (ONOO-HS-R) is an intermediate of 
nitrotyrosine formation. Generation of peroxinitrite 
leads to the activation of the latent myocardial resident 
MMPs and causes fibrosis [3]. Also, the formation of 
nitrotyrosine can be used as a measure of oxidative 
stress. The peroxisome proliferator activated receptor 
gamma (PPARγ) ameliorates oxidative stress and LVH 
[4, 5]. Reduced expression of PPAR causes LVH in a 
ventricular pressure overload model in mice [6]. In 
addition, administration of peroxisome proliferator 
reduces cardiac hypertrophy [7]. We and others have 
suggested decreased MMP activity by PPARγ 
induction [8, 9]. Although PPARγ agonists reduce 
cardiac dysfunction and induce anti-oxidant potential, 
the mechanism by which PPARγ agonist reduces LVH 
and cardiac fibrosis is unclear. We hypothesize that 
PPARγ decreases LVH and cardiac fibrosis in chronic 
pressure overload, in part, by increasing SOD, eNOS 
and elastin and decreasing NOX4 (NADPH oxidase 
subunit), MMP and collagen synthesis and 
degradation. 
2.  Materials and Methods 
Animals 
Wild-type C57BL/6J 8 weeks old male mice were 
obtained from Jackson Laboratories (Bar Harbor, 
Maine). These animals were kept in animal care facility 
of University of Louisville, where they were monitored 
daily. Animal protocols were performed in accordance Int. J. Biol. Sci. 2007, 3 
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to the National Institutes of Health guidelines and 
approved by the IACUC of the University Of 
Louisville School Of Medicine. All animals were fed 
rodent chow and housed in cycle of 12 hr light and 12 
hr dark conditions. The room was kept at 24°C. 
Pressure Overload and Systemic Hypertension 
Model 
To mimic the condition where systemic 
hypertension imposed load on the heart, abdominal 
aortic banding above the kidneys was created. The 
mice were anesthetized with 2, 2, 2 tribromoethanol 
(TBE, 100 mg/kg of body weight, I. P.) (Sigma-Aldrich, 
St. Louis, MO). A midline incision was made to expose 
the abdominal area. The abdominal aorta was 
constricted (i.e. aortic stenosis-AS) by tightening a 6-0 
nylon suture against a 25-gauge blunted needle with 
the needle being removed after the suture was secure. 
The sham animals underwent the same procedure 
without the banding. The incision was closed in layers 
and the animals were allowed to recover. Animals 
were weighed and tissues were harvested at 4 weeks 
for heart, kidneys, lungs and blood. The tissues were 
either snap frozen in liquid nitrogen or placed in 10% 
formalin. 
Treatment Groups 
To induce PPARγ, ciglitazone (CZ, CalBiochem 
Corp) 4 µg/ml was administered in drinking water for 
4  w k s .  T h e  a m o u n t  ( 4  µ g / m l )  o f  C Z  i s  s o l u b l e  i n  
aqueous conditions: the binding constant between 
ciglitazone and PPARγ is in the micromole range [10]. 
Based on the assumption that mice have a blood 
volume of ~2 ml and drink ~5 ml water/day, each will 
ingest ~2 mg/kg/day CZ. This produced a blood 
concentration of ~32 µMole/L, which was enough to 
saturate most binding sites on PPAR. In humans, 100 
mg/day PPAR agonist has a potent effect [11]. The 
mice were treated for 4 weeks and grouped into: 1) 
Sham, 2) AS; 3) Sham+CZ; 4) AS+CZ. 
Measurement of Echocardiography systolic and 
diastolic function 
A Hewlett-Packard Sonos 5500 
echocardiographic system equipped  with a 15-MHz 
shallow-focus 15-6L phased-array transducer was used 
for measurements of LV function on TBE-anesthetized 
mice. The M-mode selection allowed for the 
visualization of systole and diastole within the beating 
h e a r t .  A l s o  f r o m  M - m o d e  L V  w a l l  t h i c k n e s s  a n d  
diameter were assessed as well as ejection fraction 
(EDD-ESD/EDD).  
Western Blot 
Collagen, nitrotyrosine, SOD, NOX4, MMP, and 
TIMP-4 antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA). eNOS and iNOS were 
from BD Biosciences (Franklin Lakes, NJ). Elastin 
antibody was from Chemicon (Temecula, CA). The LV 
extracts were prepared in an overnight cacodylic acid 
extracellular buffer (10mM/L Cacodylic Acid pH 5.0, 
8.76g/L NaCl, 5mM/L ZnCl2, 2.22 g/L CaCl2, 
0.098g/L NaN3, 100 µL/L Trition X-100). The samples 
were assessed for protein concentration with a Bio-Rad 
assay (Philadelphia, PA) using the Bradford Method 
[20]. 20μg of the protein was  mixed with equal 
volumes of reducing 1x SDS sample buffer. They were 
electrophoresed on 10% SDS-PAGE gels. The gel was 
then blotted onto a polyvinylidene difluoride 
membrane. After being transferred, blots were washed 
with Tris-buffered saline  (TBS) for 5 min at room 
temperature and incubated in blocking buffer of 5% 
milk in Tris-buffered saline with 1% tween (TBST) for 1 
h at room temperature. The blots were then incubated 
with the indicated primary antibodies (3% milk in 
TBST) overnight at 4°C using slow rocking. The blots 
were washed three times (for 15-min each) with TBST 
and incubated with HRP-conjugated  secondary 
antibody (3% milk in TBST). After being washed three 
times (for 15-min  each) with TBST, the proteins of 
interest were detected using an  ECL plus kit 
(Amersham Biosciences, Piscataway, NJ). The 
membranes were then stripped using 0.2 M NaOH/ 
0.1% SDS solution for 30 min at room temperature and 
reprobed for β-actin. Band densities were normalized 
to the untreated controls and presented as percentage 
changes. 
Histology 
The heart sections were placed in 10% formalin. 
The sections then underwent a graded alcohol 
dehydration process. The sec t i o n s  w e r e  f i x e d  t o  a  
holder using paraplast and sat overnight. Then they 
were cut into 3 mm sections and stained with Sirius 
red for collagen (fibrosis) and H & E for cellularity. 
Optical light microscopy was performed at 40 X 
magnification. 
Statistical Analysis 
A sample size of n=11 was used in each group. 
The data was presented as the mean+/-SE. The 
difference was calculated statistically with the 
significance level of p < 0.05 using ANOVA followed 
by Bonferroni post hoc test.  
3.  Results 
PPARγ levels in pressure overload 
The levels of PPARγ were decreased in the LV of 
chronic pressure overload mice. The treatment with 
ciglitazone (CZ, a PPARγ agonist) mitigated the 
decrease in aortic stenosis-mediated PPARγ levels in 
mice with chronic pressure overload (Figure 1). 
Levels of oxidative stress 
To determine whether the increase in oxidative 
stress in chronic pressure overload is due to 
differential expression of Mn-SOD, NADPH oxidase, 
eNOS, iNOS and nitration of the tyrosine in proteins in 
the hearts of chronic pressure overload, we measured 
SOD, NOX4 (NADPH oxidase subunit), eNOS, iNOS 
and nitrotyrosine. Although it appears that CZ itself 
increased Mn-SOD expression (vs. sham), there were 
no change in the levels of SOD with or without AS. 
Although CZ itself increased NOX4 expression (vs. Int. J. Biol. Sci. 2007, 3 
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sham), but decreased the NOX4 expression induced by 
AS (Figure 2). The levels of eNOS was decreased in 
aortic stenosis-induced pressure overload mice, there 
w a s  n o  e f f e c t  o f  C Z  o n  t h i s  d e c r e a s e .  T h e  l e v e l s  o f  
iNOS were increased in pressure overload. The 
treatment with CZ mitigated this increase in iNOS. The 
levels of total nitrotyrosine proteins were increased in 
chronic pressure overload mice. In addition, CZ itself 
increased nitrotyrosine expression (vs. sham) (Figure 
3). These results suggest that pressure overload 
induces NOX4, and iNOS; but decreases eNOS and 
had no effect on SOD. The treatment with CZ 
ameliorated the increase in NOX4 and iNOS but had 
no decrease in eNOS levels. 
 
 
Figure 1: Western blot analysis of PPARγ in LV: The LV 
tissue homogenates from Sham, aortic-stenosis (AS), Sham + 
CZ and AS+CZ mice were prepared. The levels of PPARγ were 
measured by immuno-blots using PPARγ antibody. Beta-actin 
was used as control. The scanned data of the blots were 
represented by bar graphs. *p<0.05 compared to Sham; ** 




Figure 2: Western blot analysis of Mn-SOD, and NOX4 in LV: The LV tissue homogenates from Sham, aortic-stenosis (AS), Sham 
+ CZ and AS+CZ mice were prepared. The levels of SOD and NOX4 were measured by immuno-blots using respective antibodies. 
β-actin for equal loading; graphs represent scan data for band intensities; *p<0.05 compared to sham; ** p<0.05 compared to AS; 
n=6 in each group. 
 
Figure 3: Western blot analysis of eNOS, iNOS and total nitrotyrosine (NO2-T) in LV: The tissue homogenates from Sham, 
aortic-stenosis (AS), Sham + CZ and AS+CZ mice were prepared. The levels of eNOS, iNOS and protein nitrotyrosine were 
measured by immuno-blots using respective antibodies. β-actin was used for equal loading; graphs represent scan data for band 




The levels of MMP-2 were increased, and CZ 
mitigated this increased in AS mice. The CZ itself 
increased MMP-9 expression (vs. sham), but decreased 
the MMP-9 expression induced by AS. The levels of 
MMP-13 were increase in pressure overload, and CZ 
ameliorated this increase. To determine whether the 
increase in MMP levels is associated with decrease in 
cardiac specific TIMP (TIMP-4), we measured the 
levels of TIMP-4. The levels of TIMP-4 were decreased 
in pressure overload. The treatment with CZ mitigated 
this decrease (Figure 4). To determine whether the 
increase in MMP caused collagen breaks, we measured 
the collagen alpha-chain expression and collagen 
fragments. The results suggested that although there 
was robust increase in collagen synthesis, there was 
significant degradation (i.e. fragmentation of intact 
collagen alpha chain were increased in AS) [Figure 5]. 
To determine where cardiac fibrosis is due to increase 
in collagen/elastin, we measure elastin levels. The 
results suggest that there was decrease in elastin 
expression in chronic pressure overload. The treatment 
with CZ ameliorated both the collagen degradation 
and decrease in elastin expression (Figure 5). There 
was robust interstitial and perivascular fibrosis in the 
LV of chronic pressure overload. The treatment with 
CZ mitigated the interstitial and perivascular fibrosis 
(Figure 6).  
 
Figure 4: Western blot analysis of LV levels of MMP-2, -9, -13 and cardiac specific TIMP-4: The LV tissue homogenates from 
Sham, aortic-stenosis (AS), Sham + CZ and AS+CZ mice were analyzed for MMP-2, -9, -13 and TIMP-4 using respective 
antibodies. β-actin was used for equal loading; graphs represent scan data for band intensities; *p<0.05 compared to sham; ** p<0.05 
compared to AS; n=6 in each group. 
 
 
Figure 5: Western blot analysis of collagen (alpha-chain, 100 kDa), collagen fragments, and elastin in LV: The tissue homogenates 
from Sham, aortic-stenosis (AS), Sham + CZ and AS+CZ mice were prepared. The levels of collagen (alpha-chain), collagen 
fragments, and elastin were measured by immuno-blots using respective antibodies. β-actin was used for equal loading; graphs 




Figure 6: Representative sections of formalin-fixed tissue section analysis by histological staining with Sirius Red (SR) for collagen 
and Hematoxin-eosin (HE) for cellularity of hearts from sham, AS, sham+CZ and AS+CZ mice. 
 
Figure 7: M-mode echocardiography of sham, AS, sham+CZ and AS+CZ hearts. The white arrow indicates the LV end systolic 
diameter. Note arrow is bigger in AS than other groups. The bar graph represents the LV end systolic diameters of sham, AS, 
sham+CZ and AS+CZ mice. *p<0.05 compared to sham; ** p<0.05 compared to AS; n=6 in each group. 
 
LV function 
The M-mode Echocardiographic measurements 
revealed that there was increase in LV end-systolic and 
diastolic diameters in AS mice (Table 1 and Figure 7). 
The treatment with CZ mitigated this increase in LV 
size. These data suggested significant systolic and 
diastolic dysfunction in AS-induced pressure overload 
mice. 
 
Table 1: Gravimetric and Echocardiography parameters at 4 
weeks: Body weight (BW), heart weights (HW), and lung 
weight of sham and aortic stenosis (AS) mice treated with and 
without CZ. Left ventricular end diastolic diameter (LVEDd), 
Left ventricular end systolic diameter (LVESd), fractional 
shortening (FS), and ejection fraction (EF). 
 Sham  AS  Sham+CZ  AS+CZ 
 n=11  n=11  n=11 n=11 
Body 
weight, g 
27+1 28+2 27+1 26+2 
Heart 
weight, g 
0.11±0.01 0.21±0.02* 0.11+0.01 0.16+0.02** 
Lung 
weight, g 
0.18+0.02 0.36+0.02* 0.19+0.01 0.24+0.03** 
HW/BW 
(mg/g)  
3.7+0.4 7.2+0.7* 4.0+0.4 6.0+0.5** 
LVEDd 
(mm) 
2.79±0.06 3.76±0.04* 2.84+0.05  3.29+0.03 
LVESd 
(mm) 
1.36±0.03 2.2±0.1* 1.19+0.03 1.69+0.04** 
EF %  90±2  67±2*  92+2 83+2** 
FS %  60±2  43±1*  59+1.5 51+1** 
* p<0.05 compared with sham; ** p< 0.05 compared with AS.  Int. J. Biol. Sci. 2007, 3 
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4.  Discussion  
To determine the role of collagen degradation in 
cardiac hypertrophy, we previously [2] examined the 
effect of pressure overload on extracellular matrix 
activity, composition, cardiac function and remodeling 
in collagen mutant transgenic animals. We showed 
that pressure overload caused an increase in oxidative 
stress and expression/activity of MMP-2/9, leading to 
myocardial hypertrophy and heart failure [2]. In the 
present study we extended the notion that oxidative 
stress MMP activation with collagen degradation is a 
pre-requisite for LVH and heart failure. The 
AS-induced increase in MMP and decrease in TIMP 
was mitigated by PPARγ. There was increase in 
collagen synthesis and degradation and decrease in 
elastin content in AS-induced cardiac failure, however, 
the treatment with PPARγ normalized the levels of 
elastin and collagen degradation.   
Although we showed that CZ decreased NOX4 
levels in the LV tissues of AS-model, the effects of CZ 
on other NOX family protein expression is unclear. 
However, it would be important to examine whether 
CZ decreased NADPH oxidase activity in the LV 
tissues. Others have suggested induction of SOD and 
reduction of NOX4 by PPARγ agonist [12-14], Here we 
demonstrated a differential expression of SOD and 
NOX4 in chronic pressure overload myocardium. The 
levels of SOD did not affected but the levels of NOX4 
were ameliorated by ciglitazone in aortic stenosis 
model of systemic hypertension. This study suggested 
that PPARγ effected only the formation of super oxide, 
but had no effect on the sequestration of super oxide 
free radicals. 
Although generation of peroxynitrite leads to the 
activation of the latent myocardial resident MMPs and 
causes fibrosis, in pressure overload model, levels of 
eNOS were decreased and those of iNOS and 
nitrotyrosine were increased. CZ only ameliorated the 
i N O S  b u t  h a v e  n o  e f f e c t  o n  e N O S  o r  n i t r o t y r o s i n e  
levels. Our data suggested that CZ decreased 
MMP-2/-13 levels, even though it was not able to 
ameliorate oxidative marker, nitrotyrosine levels. It 
may suggest that CZ mediated anti-oxidative 
properties caused decrease in MMP activation. In 
addition, we observed that CZ did not ameliorate the 
increase in nitrotyrosine levels in this model. The 
differential expression of eNOS and iNOS in pressure 
overload may suggest that the location of NO is more 
important than the amount of NO. The pressure 
overload decreased eNOS and increased the iNOS. The 
generation of NO in the ECM milieu oxidized the 
TIMPs by nitrosylation and caused the activation of 
latent resident MMPs [3]. There was robust increase in 
total nitrotyrosine in AS as compared to sham. 
However, PPARγ has no ameliorative effects on eNOS 
but mitigated the induction of iNOS in AS mice. This 
may suggest that iNOS is influenced by the levels of 
PPARγ and the PPARγ directly influenced the 
expression of iNOS in pressure overload myocardium. 
PPARγ has no effect on total nitrosylation. This 
differential effects of PPARγ o n  e N O S ,  i N O S  a n d  
nitrotyrosine suggest that iNOS is influenced by 
PPARγ however the levels of nitrosylation are 
independent on PPARγ levels. 
CZ decreased MMP-2/-13, but not MMP-9 levels 
in the LV tissues. This may suggest that MMP-9 
activation is also dependent on ROS. It is a paradox 
that if CZ exerts beneficial effects on LV function in 
this model via anti-oxidative properties, the MMP 
should not be inhibited. Studies [15] reported 
interstitial collagen deposition, collagen content or 
collagen metabolites in the pathological hearts, here, 
we reported that the interstitial fibrosis in pressure 
overload was due in part to increase in MMP and 
decrease in TIMP. Because LV hypertrophy is 
associated with marked interstitial fibrosis [15], a 
decrease in MMP is associated with reduced LV 
hypertrophy, and may not justify the hypothesis that 
LV hypertrophy is due to increased MMPs. Also it is 
possible that increased MMP-9 is a compensatory 
response to increased collagen production, rather than 
a cause of LV hypertrophy. However, it is a paradox 
that MMP activation and cardiac fibrosis track 
together. This paradox can be explained by 
considering turnover of the degraded matrix proteins. 
I t  i s  w e l l  k n o w n  t h a t  b o t h  M M P - 2  a n d  - 9  a r e  
collagenases, as well as excellent elastases. Because 
turnover of elastin is slower than collagen, therefore, 
degraded elastin is replaced by oxidatively modified 
collagen, leading to fibrosis. Furthermore, the 
activation of MMP transducers proteolytic stress that 
causes myocyte hypertrophy [16].  
Previous studies have shown decrease in MMP-2 
activity and TIMP-1 expression in hypertension and 
associated cardiac fibrosis, stiffness and impaired 
cardiac diastolic relaxation [17]. The MMP-9 activation 
and decrease in TIMP-4 expression were linked to 
cardiac dilatation and heart failure [18]. This leads to 
robust increase in MMP-9/TIMP-4 ratio causing 
cardiac systolic myocyte slippage and failure. 
Although it is well known that there is significant 
systolic and diastolic dysfunction in AS-induced 
pressure overload mice. The CZ mitigates the cardiac 
dysfunction of the mice with AS, in part, by 
increasing TIMP-4. 
Coordination between angiogenesis and cardiac 
hypertrophy (LVH) is the hallmark of compensatory 
response to heart failure; however, a disruption in 
coordination between cardiac hypertrophy and 
angiogenesis contributes to the transition to heart 
failure [19]. The angiogenesis, LVH and fibrosis track 
together, therefore, in the absence of blood supply to 
the myocardium at risk, the lack of angiogenesis by 
increase angiostatic factors leads to fibrotic and LVH 
conditions. Although, it is a paradox that activation of 
MMP is needed to disruption of the matrix during 
angiogenesis and to create new blood vessels, or 
opening the collaterals, however, the peptides 
generated by MMP activation are angiostatic [20, 21]. 
Early studies by Folkman et al [20, 21] suggested 
endostatin and angiostatin generated by MMP action 
on collagen-18 and plasminogen, respectively, inhibit Int. J. Biol. Sci. 2007, 3 
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tumor angiogenesis. In addition, the vasostatin is 
generated by degradation of calreticulin [22], 
tumstatin [23], arresten [24] and canstatin [25] by 
degradation of collagen-4 and restin [26] is generated 
by degradation of collagen-15. The increase in MMPs 
(Figure 4) in pressure overload is consistent with the 
notion that MMPs cause discoordinated matrix 
degradation leading to decompensatory hypertrophy 
and heart failure by generating angiostatic factors. This 
explains however, MMP, TIMP and LVH may co-exist.  
Limitations 
One of the major concerns is the lack of the 
evidence indicating that observed effects of CZ is 
mediated by PPARγ by itself. It is known that CZ is 
known to be an agonist of PPARγ and Western blot 
analysis showed that PPARγ protein expression was 
clearly induced by CZ treatment. Figure 1 showed that 
PPARγ expression was increased in sham-operated 
heart and suggested that CZ systemically induced 
PPARγ. It is important to show whether CZ treatment 
induces PPARγ expression in others tissues including 
kidney and lung, and whether expression of 
PPARalpha or PPARdelta were not affected by CZ. In 
addition, it is important to show that CZ induces 
PPARγ at the mRNA levels.  
Second, mechanistic analyses of the PPARγ 
induction by CZ should be performed because 
thiazolidine derivatives are known to exert their effects 
by activating PPARγ or by acting as antioxidants 
independent of PPARγ activation. In vitro experiments 
to determine whether CZ induces PPARγ expression 
by PPARγ -dependent or PPARγ -independent 
mechanisms will be helpful. 
Third, we harvested heart 4 weeks after aortic 
banding. During this period, myocardium responses 
dynamically, from adaptive phase to maladaptive 
p h a s e .  T h u s ,  i n  o r d e r  t o  s h o w  t h e  e f f e c t  o f  C Z  o n  
cardiac remodeling more precisely, it is important to 
show the time-course of the gene expression, for 
example, at day 1, 7, 14 and 28. These studies are in 
progress. 
It is also likely that some synthetic PPAR 
antagonists, like GW9662, could be helpful in 
illustrating the mechanism of potential changes in the 
transcription levels. In Figure 2, we described that CZ 
increased the expression of NOX4 in the 
sham-operated group. But CZ reduced the increase of 
NOX4 expression caused by AS. Similarly, the MMP9 
result (Figure 4) has a similar paradox. Although this is 
not theoretically impossible but is certainly a bizarre 
finding and can be explained if one assumes that CZ in 
the absence of injury may stimulate the compensatory 
responses. There is a study showing that CZ can 
activate pro-MMP-2 [27]. However, it is in a different 
cell type, at the enzyme activity level, and may occur 
under a different set of conditions (like oxidative 
environment). 
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